Borosil Scientific Valuation
Is 544184 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 544184 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 544184's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 544184's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 544184?
Key metric: As 544184 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 544184's PE Ratio? | |
|---|---|
| PE Ratio | 56.1x |
| Earnings | ₹288.67m |
| Market Cap | ₹16.10b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 29.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 544184's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 42.8x | ||
524394 Vimta Labs | 34.4x | n/a | ₹16.5b |
TARSONS Tarsons Products | 58.5x | 27.7% | ₹20.9b |
WINDLAS Windlas Biotech | 31.6x | n/a | ₹20.0b |
INNOVACAP Innova Captab | 46.8x | 29.7% | ₹53.3b |
544184 Borosil Scientific | 56.1x | n/a | ₹16.1b |
Price-To-Earnings vs Peers: 544184 is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the peer average (42.8x).
Price to Earnings Ratio vs Industry
How does 544184's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 544184 is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the Asian Life Sciences industry average (30.7x).
Price to Earnings Ratio vs Fair Ratio
What is 544184's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 56.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 544184's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Bal Pharma
₹2.1b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹134.50
7D
11.6%
1Y
27.4%
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹911.45
7D
-3.5%
1Y
18.7%
Venus Remedies
₹3.9b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹298.65
7D
-1.3%
1Y
-16.9%